Lai HL, Yang L. Comprehensive impact of PPARG mutations in familial partial lipodystrophy type 3: Diagnosis, therapeutic strategies. World J Diabetes 2025; 16(4): 103675 [DOI: 10.4239/wjd.v16.i4.103675]
Corresponding Author of This Article
Liu Yang, MD, PhD, Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Avenue, Nanchang 330006, Jiangxi Province, China. ciwujia@foxmail.com
Research Domain of This Article
Endocrinology & Metabolism
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Apr 15, 2025; 16(4): 103675 Published online Apr 15, 2025. doi: 10.4239/wjd.v16.i4.103675
Comprehensive impact of PPARG mutations in familial partial lipodystrophy type 3: Diagnosis, therapeutic strategies
Heng-Li Lai, Liu Yang
Heng-Li Lai, Liu Yang, Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang 330006, Jiangxi Province, China
Author contributions: Yang L provided critical revisions to the manuscript, supervised the research process, and ensured the accuracy and integrity of the content; Yang L also acted as the corresponding author, managing communication with the journal; Lai HL drafted the initial manuscript, conducted a comprehensive review of the literature, and contributed to the design and conceptualization of the study.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest related to this manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Liu Yang, MD, PhD, Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Avenue, Nanchang 330006, Jiangxi Province, China. ciwujia@foxmail.com
Received: November 28, 2024 Revised: January 16, 2025 Accepted: January 22, 2025 Published online: April 15, 2025 Processing time: 93 Days and 22.5 Hours
Abstract
This article reviews a paper in the World Journal of Diabetes. The study uncovers the link between PPARG gene mutations and metabolic disorders, such as insulin resistance, diabetes, and hypertriglyceridemia, and emphasizes the crucial role of genetic testing in precise diagnosis and personalized treatment. This article further points out that in-depth investigation into the clinical heterogeneity of PPARG mutations and their underlying mechanisms can contribute to optimizing management strategies. Meanwhile, the development of more effective targeted therapies and the conduct of extensive genomic research are of great significance for understanding familial partial lipodystrophy type 3 and related metabolic syndromes.
Core Tip: The exploration of PPARG mutations, such as the Y151C variant, reveals the genetic basis of familial partial lipodystrophy type 3 (FPLD3) and its related metabolic syndromes. This commentary emphasizes the importance of genetic testing for precise diagnosis and treatment while advocating for further research into clinical phenotype variability and targeted therapies. Advancing personalized medicine and deepening our understanding of PPARG-related pathways can significantly improve clinical outcomes for FPLD3 patients.
